Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Posts tagged ‘Dr Michael Jensen SCRI’

We have long argued that by the time 2nd Generation CAR T cell therapies hit the market they will almost be obsolete and next generation versions will already be in advanced clinical testing. The product life cycle in this niche is likely to be a very rapid one, much more so than in other areas of cancer research.

The critical question isn’t when these new constructs will be available, but rather what form will they take? What will they look like, and which issues will they address?

Several researchers are leading the way in the CAR T cell therapy space, but a recent presentation by one expert in this field reinforced how he is making a transition from pioneer to disruptor.

In this post we explore some of the issues and ideas he discussed in a vision for the future.

To learn more, subscribers can log-in to read our latest insights or you can gain access to BSB Premium Content.

Honolulu: At the BMT Tandem meeting that ended yesterday in Hawaii, one of the hot topics was CAR T Cell Therapy. This should, perhaps, come as no surprise to readers given that bone marrow transplanters are not only the investigators doing the clinical trials, but will be the initial target market for this product.

Dr Micheal JensenOne of the pioneers in the development of adoptive cellular therapy is Michael Jensen (pictured) who is Director, Ben Towne Center for Childhood Cancer Research at Seattle Children’s Research Institute (SCRI) and the Sinegal Endowed Professor of Pediatrics at the University of Washington School of Medicine. Dr Jensen is also a scientific co-founder of Juno Therapeutics, Inc.

He’s been doing research in the field for over 20 years, and told me that not so long ago there would only be a handful of people in the room for a CAR T cell presentation!

In a plenary scientific session at the Tandem meeting, he presented to over 3,000 attendees on “CD19-Specific CAR T Cells as a Post-ALLO HSCT Relapse Salvage Therapy.”

After his presentation, he kindly spoke with BSB. This post describes some of the key take-homes from his talk.

Subscribers can login to read more or you can purchase access.

error: Content is protected !!